Semler Scientific, Inc. Q2 FY2022 Earnings Call
· Earnings call transcript and AI-powered summary
- Revenue: $14.8 million, up 4% year-over-year from $14.3 million in Q2 2021.
- Fixed Fee Revenue: $8.5 million, increased 12% YoY.
- Variable Fee Revenue: $6 million, decreased 8% YoY due to strong Q2 2021 comparables driven by pandemic-related timing shifts in customer testing.
- Equipment & Other Revenue: $300,000, increased 40% YoY.
- Net Income: $4.1 million, down 39% YoY from $6.7 million in Q2 2021.
- EPS: $0.51 per diluted share, down from $0.83 per diluted share in Q2 2021.
- Operating Expenses: $9.6 million, up 23% YoY due to increased headcount, wage inflation, higher insurance and professional fees, and expiration of pandemic-related tax credits.
- Cash Position: $40 million in cash and equivalents at quarter-end.
- Share Repurchase: Repurchased 99,000 shares ($2.8 million) at an average of $28.75/share; $17 million remains authorized for future repurchases.
Guidance & Outlook
- FY22 Revenue: Maintained at $58–$60 million.
- Operating Expenses: Revised lower to $42.5–$44 million (previously $44–$46 million).
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional